argatroban and fidexaban share 2 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.667 means 67% of the combined target set is bound by both compounds. The IDF-weighted score of 0.622 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do argatroban and fidexaban have in common?
argatroban and fidexaban share 2 molecular targets with a Jaccard similarity of 67%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can argatroban and fidexaban be combined?
argatroban and fidexaban share 2 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: argatroban or fidexaban?
In the BiohacksAI corpus: argatroban has 0 PubMed-indexed studies, fidexaban has 0 studies.